NASDAQ:BLCM - Bellicum Pharmaceuticals Stock Price, Forecast & News

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Bellicum Pharmaceuticals's stock reverse split on the morning of Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) released its quarterly earnings results on Monday, August, 5th. The biopharmaceutical company reported ($5.80) EPS for the quarter, missing analysts' consensus estimates of ($5.40) by $0.40. The biopharmaceutical company had revenue of $1.39 million for the quarter, compared to analysts' expectations of $0.23 million. Bellicum Pharmaceuticals had a negative net margin of 4,768.13% and a negative return on equity of 280.67%. View Bellicum Pharmaceuticals' Earnings History.

Bellicum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Bellicum Pharmaceuticals.

0 brokers have issued 1 year price objectives for Bellicum Pharmaceuticals' stock. Their forecasts range from $18.00 to $18.00. On average, they expect Bellicum Pharmaceuticals' stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 95.7% from the stock's current price. View Analyst Price Targets for Bellicum Pharmaceuticals.

Headlines about BLCM stock have trended very positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bellicum Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Bellicum Pharmaceuticals.

Some companies that are related to Bellicum Pharmaceuticals include Five Prime Therapeutics (FPRX), Scpharmaceuticals (SCPH), Fortress Biotech (FBIO), Evelo Biosciences (EVLO), TAIWAN LIPOSOME/S (TLC), Chiasma (CHMA), Strongbridge Biopharma (SBBP), Spero Therapeutics (SPRO), GlycoMimetics (GLYC), Akorn (AKRX), Ovid Therapeutics (OVID), Neptune Wellness Solutions (NEPT), Tyme Technologies (TYME), Avenue Therapeutics (ATXI) and Northwest Biotherapeutics (NWBO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), Cyberark Software (CYBR), TransEnterix (TRXC), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD) and FireEye (FEYE).

(BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

Bellicum Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (51.76%), Sumitomo Mitsui Trust Holdings Inc. (4.61%), Nikko Asset Management Americas Inc. (4.61%), Principal Financial Group Inc. (1.01%), ARK Investment Management LLC (0.84%) and Geode Capital Management LLC (8.35%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, David M Spencer, Jon P Stonehouse, Richard A Fair and Shane Ward. View Institutional Ownership Trends for Bellicum Pharmaceuticals.

BLCM stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Algert Global LLC, State Street Corp and Renaissance Technologies LLC. View Insider Buying and Selling for Bellicum Pharmaceuticals.

BLCM stock was bought by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Principal Financial Group Inc., Geode Capital Management LLC, Oxford Asset Management LLP, ARK Investment Management LLC, Franklin Street Advisors Inc. NC, Resources Investment Advisors LLC. and Raymond James & Associates. Company insiders that have bought Bellicum Pharmaceuticals stock in the last two years include Jon P Stonehouse, Richard A Fair and Shane Ward. View Insider Buying and Selling for Bellicum Pharmaceuticals.

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BLCM stock can currently be purchased for approximately $9.20.

Bellicum Pharmaceuticals has a market capitalization of $45.91 million and generates $1.12 million in revenue each year. The biopharmaceutical company earns $-98,040,000.00 in net income (profit) each year or ($24.40) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe.View Additional Information About Bellicum Pharmaceuticals.

The official website for Bellicum Pharmaceuticals is http://www.bellicum.com/.

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]